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ABSTRACT 
Background and Objectives: Kawasaki disease (KD) is an acute systemic vasculitis in children which causes coro-
nary arterial dilatation (CAD) and gallbladder distension (GBD). There is a dearth of investigating the relation-
ship between the severity of KD and GBD with lipid profiles. Subjects and Methods: A total of 80 patients with 
‘complete KD’ who were diagnosed from January 2005 to May 2009 was enrolled in this study. Serum cholesterol 
{total, high density lipoprotein-cholesterol (HDL-C) and low density lipoprotein-cholesterol (LDL-C)}, triglyceride 
(TG), complete blood count, inflammation markers {erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP)} were measured at the time of admission during febrile period. Echocardiography and abdominal sono-
gram were performed in all patients to determine CAD and gallbladder size. According to GBD, patients with KD 
were classified as patients with GBD and patients without GBD. Between two groups, demographic and clinical 
data were analyzed. Results: The serum level of LDL-C was significantly lower in patients with GBD (p=0.03) com-
pared with patients without GBD or febrile control. There was no significant difference in inflammatory indices 
between patients with GBD and patients without GBD. GBD was not significant risk factor of CAD in this study 
(odds ratio=2.0, 95% confidence interval=0.82-5.3, p=0.16). Conclusion: This is the first study that highlights 
the relationship between the GBD and lipid metabolism in patients with KD. This study provides clinical in-
sights about potential mechanism underpinning the relationship between the GBD and lipid metabolism. (Korean 
Circ J 2010;40:137-140) 
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Introduction 
 
Kawasaki disease (KD) is an acute systemic vasculitis 
of childhood affecting small- and medium-sized ar-
teries.
1) The inflammatory reaction of KD can lead to 
vasculitis of coronary arteries, hence this disease is con-
sidered a leading cause of acquired heart diseases in 
childhood in developed countries.
2) Characteristic cli-
nical features of KD include prolonged fever, bilateral 
bulbar nonexudative redness, mucocutaneous changes 
of lips and mouth, transient polymorphous rash, eryth-
ematous swelling of palms and soles, and cervical lymph 
node enlargement more than 1.5 cm.
1) Other manifes-
tations of KD that reflect its systemic vasculitis nature 
are sterile pyuria, hepatitis, GB hydrops, arthritis, and 
aseptic meningitis.
3) 
Among systemic findings of KD, gallbladder disten-
sion (GBD) is observed in about 8.8% of patients th-
rough ultrasonogram.
4) Abdominal sonogram is a rou-
tine diagnostic work up for KD,
5) however few case re-
ports about the significance of GBD in patients with 
KD have been published. Previous studies suggested 
that inflammation of biliary tracts may explain the ph-
enomenon of the GBD in KD.
6) Suddleson et al.
5) re-
ported that GB hydrops could be an early diagnostic 
marker in atypical KD. 
GBD has been reported in various autoimmune dise-
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ases such as rheumatoid arthritis, antiphospholipid syn-
drome, Henoch-Schönlein purpura and systemic lupus 
erythematosus.
7)8) Gallbladder is the main organ of li-
pid metabolism. When there is inflammation in the 
gallbladder, the endothelial function of gallbladder for 
recycling of lipid could be decreased.
9-11) Several reports 
suggested that the patients with coronary arterial lesions 
have the lower serum levels of total cholesterol (TC), high 
density lipoprotein-cholesterol (HDL-C), and apo A-I, 
A-II and B than those of patients without coronary ar-
terial lesions during the acute stages of KD.
10)12) While 
low density lipoprotein-cholesterol (LDL-C) or Trigly-
ceride (TG) are controversial among studies.
9)13-15) Taken 
together with the previous findings, if the inflammatory 
processes are vigorous, the endothelial functions of gall-
bladder could be decreased due to inflammatory changes 
of GB, pathologic bile duct proliferations or inflam-
matory cell interactions. As a consequence lipid profiles 
may be changed until the inflammation is subsided, 
which usually takes two weeks after acute phase.   
Recently coronary arteritis with unbalanced lipid pro-
files are explained as aberrant autoimmune reactions
16) 
and the increased levels of proinflammatory cytokines 
such as tumor necrosis factor-α  (TNF-α), interleukin-
6 (IL-6), and IL-1β.
17)18) Lipid profiles as well as C-re-
active protein (CRP) may be related with the severity of 
inflammatory autoimmune vasculitis.
13)17) 
The purpose of this study is to assess the association 
of severity of KD and GBD with lipid profiles.   
 
Subjects and Methods 
 
Patient population 
A total of 80 patients who were diagnosed as com-
plete KD in Wonju Christian Hospital from January 
2005 to May 2009 were enrolled in this study. The de-
mographic characteristics of patients including age, 
gender, and previous KD history were recorded at the 
time of admission. 
They met the diagnostic criteria for KD and were fol-
lowed up by the same cardiologist. Echocardiography 
was performed in all patients to examine coronary ar-
terial dilatation (CAD) and any other cardiac lesions. 
We determined CAD according to criteria as following. 
If the patient is younger than 5 year old, according to 
the body weight, if it is over 15 kg, CAD is defined as 
more than 3.0 mm, if it is less than 15 kg, as more than 
2.5 mm. In patients whose age is above 5 years of age, 
CAD is defined as more than 4.0 mm. 
Abdominal sonogram was performed in all patients 
to measure GB size by the same radiologist. GB size was 
measured by length and width.
20) GBD was defined as 
more than 2 standard deviation of the age matched av-
erage values of length and width.   
Patients with KD were classified into two groups ac-
cording to the GB size, patients with GBD and patients 
without GBD. Febrile controls were recruited. The fe-
brile controls was composed of 20 patients who were 
admitted with urinary tract infection and taken abdo-
minal sonogram. 
Fasting serum TC, HDL-C, LDL-C, TG, complete 
blood count, erythrocyte sedimentation rate (ESR), and 
CRP were measured at the time of admission when the 
patients had fever.   
 
Statistical analysis   
The SAS version 9.1 (SAS Institute Inc., Cary, NC, 
USA) was used to perform all statistical analysis. The 
demographic data and lipid profiles from each group 
were compared using analysis of variance. The data of 
inflammatory indices from patients with GBD group 
and patients without GBD group were compared using 
t-test. Pearson correlation analysis was used to assess 
the correlation between GBD and CAD with adjustment 
of age. 
Statistical significance was set at p<0.05 was consi-
dered statistically significant. 
 
Results 
 
The demographic characteristics of study populat-
ion are shown in Table 1. Out of a total 80 patients with 
typical KD, 26 patients had GBD and 54 patients had 
no GBD. There were 3 cases of relapse and 2 cases of re-
fractory KD. Among patients with GBD, seven patients 
had abdominal pain whose liver enzyme levels were ele-
vated. Sixteen patients had elevated levels of aspartate 
aminotransferase or alanine aminotransferase. Abdomi-
nal mass was not evident in all children.   
The main difference in lipid profile between two groups 
was LDL-C level. In acute phase of KD, LDL-C level 
was significantly lower in the GBD group (p=0.0030). 
There was no significant difference in TC, TG, HDL-
C, or TC/HDL-C levels among three groups (Table 2). 
There was no significant difference in inflammatory 
indices between patients with GBD and patients with-
out GBD (Table 3). In addition, there was no signifi-
cant difference of frequency of intravenous immuno-
globulin (IVIG) treatment between two groups. One re-
lapse case and one refractory KD were included in GBD 
group; two relapse cases and one refractory KD were in-
Table 1. Demogrphic characteristics of patients with Kawasaki 
disease and febrile controls 
Parameter  Patients 
with GBD 
Patients  
without GBD 
Febrile
control
Number 26  54  20 
Mean age (year)  1.88±2.27 2.33±1.98 1.79±2.32
Gender ratio (M:F) 23:3 29:25 9:11 
CAD 17  10  00 
GBD: gallbladder distension, CAD: coronary arterial dilatation
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cluded in no GBD group.   
When we determined the GBD more than 2SD of 
mean GB size according to age, GBD was not proved 
to be a significant risk factor of CAD (odds ratio=2.0, 
95% confidence interval=0.82-5.3, p=0.16). When 
stratified with age, GB width and right coronary artery 
(RCA) size only showed significant correlation (p<0.001); 
however, other parameters did not show significant as-
sociations.  
 
Discussion 
 
Kawasaki disease is an acute febrile illness of child-
hood characterized by clinical laboratory and histopa-
thological features of systemic small- and medium-sized 
vascular inflammation.
20) Marked activation of the im-
mune system during acute phase of KD such as increas-
ed cytokine production by activated effector cells leads 
to coronary arterial lesions.
21-23) The treatment of KD is 
based on two goals, the reduction of inflammation and 
prevention of the long-term sequelae. High-dose IVIG 
therapy with aspirin is effective in resolving inflamma-
tion and reducing occurrence of coronary arterial abnor-
malities.
24)25) 
Immunoregulatory mechanisms of IVIG in KD are 
explained as following: 1) modulation of cytokine pro-
duction, 2) neutralization of bacterial superantigens or 
other etiologic agents, 3) augmentation of T-cell sup-
pressor activity, 4) suppression of autoantibody synthesis, 
and 5) provision of anti-idiotypic antibodies.
26) 
Lipid profiles may be changed by endothelial dysfunc-
tion of the inflammed gallbladder, which can be one 
of the risk factors of coronary arterial disease.
13) In this 
study, only LDL-C level was significantly lower in the 
patients with GBD. Other lipid profiles did not show any 
difference among three groups. Because we detected li-
pid profiles in acute phase and LDL-C level was de-
creased, which is compatible result of Chiang et al.
15) 
However, there are some reports that LDL-C level is 
higher in patients with KD than controls.
9)13) These stu-
dies were done in subacute phase of KD
13) and the mean 
age was higher than our study (7.6 year old vs. 2.68 year 
old).
9) The cause of transient decrease in LDL-C level 
is unknown. However, oxidized LDL-C is involved in 
the pathogenesis of vasculitis so transient consumption 
of LDL-C in acute inflammation may be suggested as 
a possible cause. Fast consumption and late synthesis 
due to GB dysfunction are yet to be determined in KD. 
Various inflammatory indicies such as the count of 
white blood cells, ESR, and CRP were measured. In this 
study, GBD failed to show the association with inflam-
matory indices. GBD is thought to be secondary change 
from processes of vasculitis in the GB wall or an in-
flammatory change of bile duct.
7) Therefore, GBD may 
be considered to be an another candidated clinical bio-
marker of inflammation in KD.   
Statin, hydroxymethylglutaryl coenzyme A reductase 
inhibitor, was proved to be effective to reduce cholesterol 
levels and improve surrogate inflammatory markers of 
atherosclerosis or cardiovascular disease.
27) According to 
Huang et al.
28) a short-term statin therapy appeared to 
significantly improve chronic vascular inflammation and 
endothelial dysfunction without adverse effects in child-
ren who were complicated by coronary artery abnor-
mality after KD. Before administering statin in KD, the 
basic data about lipid metabolism in KD would be re-
quired first. As far as we know, our report is the first study 
to investigate an association between GBD and CAD. 
We demonstrated that there was a significant relation-
ship between GB width and RCA diameter (p<0.001). 
Although this relationship was apparent when we st-
ratified our subjects according to the age factor, this may 
be explained by anthropometical changes in GB and 
RCA. However, this assumption should be elucidated 
Table 2. Lipid profiles among patients with GBD, patients without GBD, and febrile controls
Parameter  Patients with GBD  Patients without GBD  Febrile control  p 
TC (mg/dL)  145.62±31.76 147.41±34.08 148.65±33.44 0.9520
TG (mg/dL)  126.58±52.24 110.56±48.38 136.55±93.64 0.3850
HDL-C (mg/dL)  33.77±15.26 34.48±12.32 40.55±14.58 0.2231
LDL-C (mg/dL)  72.65±23.29 82.56±30.08 101.93±30.06 0.0030
TC/HDL-C 5.61±4.44 4.72±1.63 4.19±1.89 0.2677
GBD: gallbladder distension, TC: total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipo-
protein-cholesterol 
 
Table 3. Comparison of inflammatory indicies in patients with Kawasaki disease according to gallbladder distension 
Inflammatory indicies  Patients with GBD  Patients without GBD  p 
WBC (count/μL) 13358.52±7025.35 12220.37±4941.17 0.3253
ESR (mm/hour)  62.84±37.91 66.81±35.15 0.6942
CRP (mg/dL)  7.04±6.43 6.22±6.04 0.6325
Platelet (count/μL) 402703.70±123551.45 413111.11±217946.59 0.9177
GBD: gallbladder distension, WBC: white blood cell, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein 
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with a larger sample size and robust experimental design. 
Several additional shortcomings of this study should 
be considered in future research. One is that it was a 
retrospective study performed in a single tertiary medi-
cal center. The second limitation is that the change of 
lipid profiles in subacute phase was not checked. We 
could not observe the changes of lipid profiles in sub-
acute phase of KD and compare with those of acute 
phase. The third limitation is an age factor. In the pre-
sent study, we included infants who have reversible GBD, 
which may have confounded accurate measurement of 
GB size due to fasting, intravenous nutrition, and obe-
sity beside inflammation.
29) Therefore, it would be li-
mited to generalize our findings to the relationship bet-
ween GBD and inflammation to interpretation of GBD 
in infants with KD. 
Further studies should examine the long-term lipid 
profiles and inflammatory biomarkers in KD, which 
will provide invaluable information for effective manage-
ment of chronic sequelae of KD. In conclusion, althou-
gh our data failed to prove that GBD could be another 
biomarker of KD, they may be valuable as a basic study 
for suggesting the association of lipid profiles, GBD, 
and inflammatory markers of KD.   
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